Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 11/20 | 0.63 |
| ▸ | ADRA2C | P18825 | 10/20 | 0.63 |
| ▸ | ADRA2B | P18089 | 9/20 | 0.63 |
| ▸ | ADRA1A | P35348 | 9/20 | 0.63 |
| ▸ | ADRA1D | P25100 | 7/20 | 0.63 |
| ▸ | ADRA1B | P35368 | 7/20 | 0.63 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.54 |
| ▸ | HTR1D | P28221 | 3/20 | 0.53 |
| ▸ | HTR1B | P28222 | 2/20 | 0.50 |
| ▸ | CFB | P00751 | 3/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flutonidine SCHEMBL29367926 | 1.00 | ADRA2A (0.63) | ADRA2AADRA2CADRA2BADRA1AADRA1D | |
| SCHEMBL5903662 | 0.88 | ADRA2A (0.63) | ADRA2AADRA2CADRA2BADRA1AADRA1D | |
| SCHEMBL11757404 | 0.82 | ADRA2A (0.63) | ADRA2AADRA2CADRA2BADRA1AADRA1D | |
| SCHEMBL8020019 | 0.78 | ADRA2A (1.00) | ADRA2AADRA2CADRA2BADRA1AADRA1D | |
| SCHEMBL8009989 | 0.76 | ADRA2A (0.56) | ADRA2AADRA2CADRA2BADRA1AADRA1D | |
| SCHEMBL5827504 | 0.76 | HTR1D (0.66) | ADRA2AADRA2CADRA2BADRA1AADRA1D | |
| SCHEMBL8989309 | 0.76 | ADRA2A (0.60) | ADRA2AADRA2CADRA2BADRA1AADRA1D | |
| SCHEMBL13907367 | 0.75 | LMNA (0.53) | ADRA2AADRA2CADRA2BADRA1AADRA1D | |
| SCHEMBL13024513 | 0.74 | ADRA2A (0.79) | ADRA2AADRA2CADRA2BADRA1AADRA1D | |
| SCHEMBL11192127 | 0.73 | ADRA2A (0.52) | ADRA2AADRA2CADRA2BADRA1AADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3359134-B1 | COMPOSITIONS AND COMPOSITIONS FOR USE IN ON-DEMAND HIGH-EFFICIENCY TRIGGERABLE ANESTHESIA | CHILDRENS MEDICAL CT CORP (US) | 2025-04-09 | — | — | EP | claimed |
| US-11344498-B2 | Compositions and methods for on-demand high-efficiency triggerable anesthesia | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-05-31 | — | — | US | claimed |
| US-20190070115-A1 | Compositions and Methods for On-Demand High-Efficiency Triggerable Anesthesia | THE CHILDREN'S MEDICAL CENTER CORPORATION | 2019-03-07 | — | — | US | claimed |
| WO-2017062875-A1 | COMPOSITIONS AND METHODS FOR ON-DEMAND HIGH-EFFICIENCY TRIGGERABLE ANESTHESIA | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2017-04-13 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20150093435-A1 | TREATMENT OF LENGTH DEPENDENT NEUROPATHY | ARC1, INC. | 2015-04-02 | — | — | US | claimed |
| US-8026266-B2 | Treatment of length dependent neuropathy | ARCION THERAPEUTICS, INC. (US) | 2011-09-27 | — | — | US | claimed |
| EP-2343068-A2 | Treatment of length dependent neuropathy | Arcion Therapeutics, Inc. (US) | 2011-07-13 | — | — | EP | claimed |
| US-20110142920-A1 | TREATMENT OF LENGTH DEPENDENT NEUROPATHY | ARCION THERAPEUTICS, INC. | 2011-06-16 | — | — | US | claimed |
| US-RE41998-E1 | Compositions and methods of treatment of sympathetically maintained pain | Arclon Therapeutics, Inc. (US) | 2010-12-14 | — | — | US | claimed |
| EP-1962836-A2 | TREATMENT OF LENGTH DEPENDENT NEUROPATHY | Arcion Therapeutics, Inc. (US) | 2008-09-03 | — | — | EP | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| US-20070142385-A1 | TREATMENT OF LENGTH DEPENDENT NEUROPATHY | ARC1, INC. | 2007-06-21 | — | — | US | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| WO-2007056460-A2 | TREATMENT OF LENGTH DEPENDENT NEUROPATHY | ARCION THERAPEUTICS, INC. (US) | 2007-05-18 | — | — | WO | claimed |
| EP-0573581-A4 | COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN | ARC 1 INC (US) | 1994-06-29 | — | — | EP | claimed |
| EP-0573581-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN | ARC 1, Inc. (US) | 1993-12-15 | — | — | EP | claimed |
| WO-1992014453-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN | ARC 1, INC. (US) | 1992-09-03 | — | — | WO | claimed |
| US-4557934-A | ALONG WITH A DIOL PYRROLIDONE OR AN AZACYCLOPENTAN-2-ONE | THE PROCTER & GAMBLE COMPANY (US) | 1985-12-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150093435-A1 | TREATMENT OF LENGTH DEPENDENT NEUROPATHY | ADRB2, ADRA2A, NGF | ADRA2A 2/4885ADRA2C 4/4885ADRA2B 7/4885 |
| US-20110142920-A1 | TREATMENT OF LENGTH DEPENDENT NEUROPATHY | ADRB2, ADRA2A, NGF | ADRA2A 2/4885ADRA2C 4/4885ADRA2B 7/4885 |
| US-11344498-B2 | Compositions and methods for on-demand high-efficiency triggerable anesthesia | CACNB1, CACNA1S, CACNA1D | ADRA2A 14/4885ADRA2C 24/4885ADRA2B 8/4885 |
| US-20190070115-A1 | Compositions and Methods for On-Demand High-Efficiency Triggerable Anesthesia | CACNB1, CACNA1S, CACNA1D | ADRA2A 14/4885ADRA2C 24/4885ADRA2B 8/4885 |
| US-20070142385-A1 | TREATMENT OF LENGTH DEPENDENT NEUROPATHY | ADRB2, ADRA2A, NGF | ADRA2A 2/4885ADRA2C 4/4885ADRA2B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.